$ZBH · ZIMMER BIOMET HOLDINGS, INC.
Zimmer Biomet filed an 8-K (Item 2.02) reporting Q3 FY2026 results. Net sales rose 3.1% reported to $2.063B, with GAAP diluted EPS of $1.00 (down 13.8%) and adjusted diluted EPS of $1.90, flat year over year. The company raised full-year 2026 guidance: reported revenue growth to 4.4%–4.9%, organic constant-currency growth to 3.0%–3.5%, and adjusted diluted EPS to $8.50–$8.60.
- Q3 net sales of $2.063B, up 3.1% reported and 3.7% constant currency.
- GAAP diluted EPS fell 13.8% to $1.00; adjusted diluted EPS was $1.90, flat YoY.
- Operating cash flow of $560.0M and free cash flow of $372.4M in Q3.
- FY26 adjusted EPS guidance raised to $8.50–$8.60 from $8.47–$8.59.
- Knees declined 3.1% while Hips grew 6.0% and S.E.T. grew 6.8%.
Extended-hours trading pushed shares to $100.00, up 3.03% versus the $97.06 regular close, signaling a positive initial reaction to the guidance raise.
A guidance raise on both revenue and adjusted EPS, despite a declining Knees franchise, signals confidence in the diversification strategy.
Orthopedic peers are seeing mixed procedure volumes; Zimmer's diversification into S.E.T. and robotics offset a 3.1% decline in its core Knees franchise.
Knees, the largest category, declined 3.1% reported, and GAAP EPS fell 13.8% on higher operating expenses and acquisition/integration costs.